Albany Molecular Research (AMRI) Enters Multi-Year Supply Agreement with Shire
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
AMRI (Nasdaq: AMRI) announced that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, Inc. which product has been in AMRI's portfolio through the required stages of development. Shire plc, is a leading global biotechnology company focused on developing and marketing innovative medicines for patients with rare diseases and other highly specialized conditions. The terms of the agreement are confidential. This is the second such multi-year agreement between AMRI and Shire, as AMRI has also been supplying a key neuroscience product to Shire.
"This agreement builds on the long-standing development and manufacturing relationship between Shire and AMRI," said William S. Marth, President and CEO of AMRI. "This long term contract with Shire illustrates our global and growing integrated API contract manufacturing business well and we look forward to continuing our relationship."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Digital Ally (DGLY) Refutes TASER's Attack on ‘292 Patent; Says Nothing New Here
- bluebird bio (BLUE) Names New COO and New SVP of Europe
- Celgene (CELG) to Acquire Acetylon Pharmaceuticals
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!